



*DPW*  
*cc*

Practitioner's Docket No.: 0003.0514/PC25968

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Babcock et al.

Group Art Unit: 1797

Serial No.: 10/590,989

Examiner: Menon, Krishnan S.

Filed : August 29, 2006

Title : Method and Device for Evaluation of Pharmaceutical Compositions

601 SW 2nd Ave., Ste 1600  
Portland, OR 97204  
Tel. No. (503) 227-5631  
FAX: (503) 228-4373

March 30, 2009

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**BEFORE MAILING OF EITHER A FINAL ACTION**  
**OR NOTICE OF ALLOWANCE (37 CFR § 1.97(c))**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**TIME OF TRANSMITTAL OF ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage, as set forth in § 1.491, of the international application or after the mailing date of a first office action on the merits, whichever event occurred last, but before the mailing date of either:
  - (1) a final action under §1.113 or
  - (2) a notice of allowance under § 1.311,

04/02/2009 LNGUYEN1 00000002 10590989

01-FC:1806

180.00 OP

04/02/2009 LNGUYEN1 00000002 10590989

01 FC:1806

180.00 OP

STATEMENT OR FEE

2. Accompanying this transmittal is:

A. ☐ a statement as specified in 37 CFR § 1.97(e).

OR

B. ☒ the fee set forth in 37 CFR § 1.17(p) for submission of an information disclosure statement under § 1.97(c).

METHOD OF PAYMENT OF FEE

3. ☒ Attached is a ☐ check ☒ Credit Card Payment Form \$180.00

PTO-2038 in the amount of: \_\_\_\_\_

Authorization is hereby made to charge the amount of \_\_\_\_\_

☒ to Deposit Account No. 03-1550 \_\_\_\_\_

☐ to credit card shown on the attached authorization form PTO-2038.

☒ Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

In accordance 37 CFR § 1.97(h), the filing of this information disclosure statement will not be regarded as an admission that any reference or combination of references referred to herein is, or is considered to be, material to patentability under 37 CFR § 1.56(b) unless specifically designated as such.



Tel. No. 503.227.5631

Dennis E. Stenzel

Reg. No. Reg. 28,763